Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B2b34b6c5d3ccd74a7a4d07d769522021> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B2b34b6c5d3ccd74a7a4d07d769522021 NCIT_P378 "NCI" @default.
- B2b34b6c5d3ccd74a7a4d07d769522021 type Axiom @default.
- B2b34b6c5d3ccd74a7a4d07d769522021 annotatedProperty IAO_0000115 @default.
- B2b34b6c5d3ccd74a7a4d07d769522021 annotatedSource NCIT_C91076 @default.
- B2b34b6c5d3ccd74a7a4d07d769522021 annotatedTarget "A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation." @default.